Open Access. Powered by Scholars. Published by Universities.®

Engineering Commons

Open Access. Powered by Scholars. Published by Universities.®

143,286 Full-Text Articles 164,676 Authors 56,080,941 Downloads 297 Institutions

All Articles in Engineering

Faceted Search

143,286 full-text articles. Page 3872 of 4085.

Influence Of Host Cell Defence During Influenza Vaccine Production In Mdck Cells, Timo Frensing, Claudius Seitz, Bjoern HeynischOtto-von-Guericke, Udo Reichl 2010 Max-Planck-Institute for Dynamics of Complex Technical Systems

Influence Of Host Cell Defence During Influenza Vaccine Production In Mdck Cells, Timo Frensing, Claudius Seitz, Bjoern Heynischotto-Von-Guericke, Udo Reichl

Vaccine Technology III

For cell culture-based influenza vaccine production virus yield optimisation is of crucial importance. In particular, with the recent threat of the new H1N1 pandemic, not only seasonal vaccines but also pre-/pandemic vaccines have to be supplied in large quantities. In vivo influenza replication is limited by the immune system, but for production cell lines the impact of cellular defence mechanisms on virus yield is unknown. In influenza-infected adherent Madin-Darby canine kidney (MDCK) cells the interferon (IFN) response and subsequent induction of the antiviral state was monitored. Virus yield and host cell signalling intensity were strain-dependent. By over-expression of viral ...


Development Of Recombinant Protein Based Chemical Conjugate Malaria Vaccines Targeting The Pre-Erythrocytic Stage, Transmission Blocking, Or Both, David L. Narum, Nicholas MacDonald, David Jones, Ruth Ellis, Yimin Wu, Patrick E. Duffy 2010 Laboratory of Malaria Immunology and Vaccinology, NIAID, NIH

Development Of Recombinant Protein Based Chemical Conjugate Malaria Vaccines Targeting The Pre-Erythrocytic Stage, Transmission Blocking, Or Both, David L. Narum, Nicholas Macdonald, David Jones, Ruth Ellis, Yimin Wu, Patrick E. Duffy

Vaccine Technology III

The development of a Plasmodium falciparum malaria vaccine is critical for future control and elimination programs. Recombinant protein based chemical conjugate vaccines, covering different parasite stages, are being developed due to complexity of the parasite and sub-optimal immunogenicity of recombinant malaria proteins in humans, respectively. Chemical conjugation of recombinant malaria proteins to carrier proteins improves their immunogenicity in animal studies. A transmission blocking vaccine comprised of the ookinete protein Pfs25 chemically conjugated to Pseudomonas aeruginosa ExoProtein A (EPA) is currently being developed for pilot scale cGMP production. Bulk lots of Pfs25 and EPA have already been produced and released following ...


Building Process Understanding For Vaccine Manufacturing Using Data Mining, Matthew Wiener 2010 Merck & Co.

Building Process Understanding For Vaccine Manufacturing Using Data Mining, Matthew Wiener

Vaccine Technology III

The production of vaccines is a complex biological process, with long cycle times and a high level of variation in raw materials, biological growth rates, and test methods. While long-term shifts or cycles in yield are not unusual, it is important to build understanding of the causes of shifts and cycles, for greater control and predictability. Hundreds of variables are monitored for every batch of vaccine produced; however, the relationships between product quality and the many process variables are difficult to quantify. In this article, we describe how mining historical process data using random forests and partial least squares (PLS ...


The Challenge Of Developing New Generation Vaccines For Control And Eradication Of Foot And Mouth Disease In South America, Susana Levy 2010 Biogénesis-Bagó, Argentina

The Challenge Of Developing New Generation Vaccines For Control And Eradication Of Foot And Mouth Disease In South America, Susana Levy

Vaccine Technology III

Foot and mouth disease (FMD) is a highly infectious viral disease that affects food producing animals such as cattle, pigs and sheep. The FMD status given by the World Organization for Animal Health (OIE) has a huge financial impact on countries that have economies based on meat trade. In the past 15 years the MERCOSUR countries (Argentina, Brazil, Paraguay and Uruguay) have consolidated industrial processes to supply the region with safe and efficacious vaccines to prevent FMD in livestock. Control and eradication programs rely heavily on compulsory vaccination with multivalent whole virus inactivated vaccines. Currently, vaccines are industrially obtained by ...


Process Scale-Up And Optimization For Production Of High Efficacy Oral Rabies Vaccine, Amine Kamen, Chun Fang Shen, Stephane Lanthier, Danielle Jacob, Johnny Montes, Andrew Beresford 2010 National Research Council / Biotechnology Research Institute

Process Scale-Up And Optimization For Production Of High Efficacy Oral Rabies Vaccine, Amine Kamen, Chun Fang Shen, Stephane Lanthier, Danielle Jacob, Johnny Montes, Andrew Beresford

Vaccine Technology III

Rabies is an important causative agent of disease resulting in an acute infection of the nervous system and death of the individual. Rabies remains an important public health program in developing countries, and the indigenous threat of rabies continues in developed countries because of wildlife reservoirs. Globally, there are about 55,000 fatal human cases of rabies each year [WHO, 2007]. Control of rabies in wildlife remains an important challenge for government offices.

There are numbers of rabies vaccines commercially available for controls of wildlife rabies. However, these vaccines currently distributed to wildlife do not effectively immunize all at-risk species ...


Cim Technology: Enabeling Economic Vaccine Purification, Matjaz Peterka, Franci Smrekar, Tony Brazzale, Marko Banjac, Petra Kramberger, Milos Barut, Ales Podgornik, Ales Strancar 2010 BIA Separations, Slovenia

Cim Technology: Enabeling Economic Vaccine Purification, Matjaz Peterka, Franci Smrekar, Tony Brazzale, Marko Banjac, Petra Kramberger, Milos Barut, Ales Podgornik, Ales Strancar

Vaccine Technology III

Vaccines are diverse and complex biological molecules, complexes and particles. Different production technologies are used for vaccines manufacturing and every production process require somekind of vaccine purification. Purification of vaccines is technically challenging and was traditionally inefficient and partially neglected due to different economical and technical reasons. Density gradient ultracentrifugation, introduced in1960s is still a major purification step for many vaccines present on the market. As a complementary techniques, cross flow filtration and chromatography has been used. Conventional chromatography supports designed for protein purification have relatively small pore sizes with restricted access for large molecules and viruses. In addition mass ...


Establishing A Platform For Spray Drying Inhalable Vaccines In South Africa, Willem Germishuizen, L Venter, A Khosa, F Mudau, P.B. Fourie, B Pulliam, M Kabadi, A Schiermeier, D.A . Edwards 2010 Medicine in Need South Africa

Establishing A Platform For Spray Drying Inhalable Vaccines In South Africa, Willem Germishuizen, L Venter, A Khosa, F Mudau, P.B. Fourie, B Pulliam, M Kabadi, A Schiermeier, D.A . Edwards

Vaccine Technology III

Mycobacterium bovis BCG is the current vaccine for tuberculosis (TB). However, BCG as it is currently administered shows highly variable efficacy in protecting adults against TB. The natural route of infection of TB is via inhalation of bacilli-containing aerosols and it is postulated that immunization by the natural route of infection may lead to a greater immunity given the fact that the lungs are the primary target of infection. By eliciting both local and systemic immune responses, it is anticipated that an inhaled form of BCG will offer greater protection against pulmonary TB.

Current commercial BCG vaccine preparations are filled ...


Rna Based Plasmid Selection System For Antibiotic-Free Plasmid Dna Vector Production, Aaron E. Carnes, Jeremy Luke, Justin Vincent, Clague Hodgson, James Williams 2010 Nature Technology Corporation, USA

Rna Based Plasmid Selection System For Antibiotic-Free Plasmid Dna Vector Production, Aaron E. Carnes, Jeremy Luke, Justin Vincent, Clague Hodgson, James Williams

Vaccine Technology III

Antibiotic resistance markers, typically kanamycin resistance (kanR), allow selective retention of plasmid DNA during bacterial fermentation and are the most commonly utilized selectable markers. However, to ensure safety, regulatory agencies recommend elimination of antibiotic resistance markers from therapeutic and vaccine plasmid DNA vectors. The presence of an antibiotic resistance gene in the plasmid backbone is considered undesirable by regulatory agencies, due to: 1) the potential transfer of antibiotic resistance to endogenous microbial flora; and 2) the potential activation and transcription of the genes from mammalian promoters after cellular incorporation into the genome. Here, we describe the development and application of ...


Escherichia Coli Plasmid Dna Fermentation: Strain And Process-Specific Effects On Vector Yield, Quality, And Transgene Expression, Aaron E. Carnes, Jeremy Luke, Justin Vincent, Clague Hodgson, James Williams 2010 Nature Technology Corporation, USA

Escherichia Coli Plasmid Dna Fermentation: Strain And Process-Specific Effects On Vector Yield, Quality, And Transgene Expression, Aaron E. Carnes, Jeremy Luke, Justin Vincent, Clague Hodgson, James Williams

Vaccine Technology III

To commercialize DNA medicines, industrial plasmid DNA manufacturing processes are needed which meet the quality, economy, and scale requirements projected for future products. NTC has developed an inducible fed-batch fermentation process that incorporates novel cell bank and fermentation process innovations that reduce plasmid mediated metabolic burden. This process also incorporates a scalable plasmid induction profile that, in combination with vector backbone modifications that double fermentation productivity compared to existing high copy vectors such as pVAX1 and gWIZ, form a generic plasmid DNA production platform driving high plasmid yields up to 2.6 g/L, with specific yields of 5% of ...


Development Of Protein Capsular Matrix Vaccine (Pcmv) Technology, Kevin P. Killeen, Ann Thanawastien, Tom Griffin 2010 Matrivax Research & Development Corp.

Development Of Protein Capsular Matrix Vaccine (Pcmv) Technology, Kevin P. Killeen, Ann Thanawastien, Tom Griffin

Vaccine Technology III

Matrivax R&D Corp. is a start-up biotechnology company with R&D operations located in Boston, USA and a vaccine pilot facility in Haikou, China. We are developing a proprietary vaccine process that entraps polysaccharides in a cross-linked protein ‘carrier’ or matrix, termed Protein Capsular Matrix Vaccine (PCMV), as an alternative to conjugate vaccine technology. Despite highly efficacious pneumococcal vaccines such as Prevnar®, S. pneumoniae causes > 1 million deaths worldwide annually. Likewise, typhoid fever afflicts ~16 million people, resulting in 600,000 deaths despite effective vaccines such as Typhim Vi® and Ty21a. The premise is that inexpensive,efficacious polysaccharide vaccines ...


A Vaccine Prototype Using Baculovirus Expression System For The Control Of Avian Influenza Virus, Mauricio Realpe, R. Mora, L. Castellanos, F. Robles, C. González-Hernández 2010 BOEHRINGER-INGELHEIM VETMEDICA

A Vaccine Prototype Using Baculovirus Expression System For The Control Of Avian Influenza Virus, Mauricio Realpe, R. Mora, L. Castellanos, F. Robles, C. González-Hernández

Vaccine Technology III

A clade 1 sequence of H5 haemaglutinin from an Asian Avian H5N1 isolate was used as a the template to chemically synthetize a codon optimized version for expression in insect cells. A single clone was chosen for expression optimization and changes were introduced in order to maximize the amount of protein to be produced and to resemble another sequence demonstrated to be present in an isolate causing disease in Humans.

Preliminary analysis at lab scale have shown promising yields of the haemaglutinin using an activity titration assay and an ELISA-based detection method. Optimization of the cell seeding, MOI, and time ...


Poly-Methyl Vinyl Ether-Co-Maleic Anhydride Nanoparticles As Antigen Delivery And Activating Systems, Carlos Gamazo, Ibai Tamayo, Ana I. Camacho 2010 University of Navarra, Spain

Poly-Methyl Vinyl Ether-Co-Maleic Anhydride Nanoparticles As Antigen Delivery And Activating Systems, Carlos Gamazo, Ibai Tamayo, Ana I. Camacho

Vaccine Technology III

The incorporation of antigens into poly-methyl vinyl ether-co-maleic anhydride nanoparticles (NP) has demonstrated to enhance the immune responses in terms of a potent Th1-adjuvant capacity. This fact may be explained by the implemented possibilities that NP render to the antigen: controlled release from the vehicle and chemotaxis for APC recruitment. Besides, after oral administration, it was reported that the bioadhesive nature of the polymer enhanced the interaction of the particulate-adjuvant to the gut mucosa. Moreover, these NP allow the adhesion of antigens and ligands to its outer shell, creating high antigen density surfaces that increase the possibilities of antigen recognition ...


Human Cells For Prostate Cancer Vaccine Therapy - The Impact Of Centrifugation Upon Key Product Quality Attributes, Michael Delahaye, Katherine Lawrence, Carol Chu Mike Hoare, Stephen Ward 2010 University College London, London

Human Cells For Prostate Cancer Vaccine Therapy - The Impact Of Centrifugation Upon Key Product Quality Attributes, Michael Delahaye, Katherine Lawrence, Carol Chu Mike Hoare, Stephen Ward

Vaccine Technology III

Centrifugation is a unit operation used within a wide range of bioprocesses, including the production of a whole cell cancer vaccine to treat Hormone Refractory Prostate Cancer (HRPC) which has been tested in Phase II clinical trials. To quantify the effect of centrifugation-related stresses upon a whole cell vaccine population, a design of experiments (DOE) based investigation at micro-scale was implemented. Qualification of the cells may be by membrane integrity and by surface marker density as well as cytokines released and retained during bioprocessing. These and possibly other factors combine to affect the biopotency of the cells and their clinical ...


Ultra-Scale Down Studies Of Human Cell Bioprocessing For A Prostate Cancer Vaccine Therapy - The Impact Of Capillary Shear, Juan Pablo Acosta Martinez, Katherine Lawrence, Carol Chu Mike Hoare, Stephen Ward 2010 University College London

Ultra-Scale Down Studies Of Human Cell Bioprocessing For A Prostate Cancer Vaccine Therapy - The Impact Of Capillary Shear, Juan Pablo Acosta Martinez, Katherine Lawrence, Carol Chu Mike Hoare, Stephen Ward

Vaccine Technology III

The scale-up and manufacturing of therapies based on intact whole cells presents a major challenge for development scientists and engineers due to the stress-reactive nature of these cells. The administrated cells may be characterized in terms of their membrane integrity and their surface markers and eventually their biopotency. The challenge is to process the cells at various scales and in a way which maintains these cell properties. Also during formulation the presence of cytokines produced by cells prior to their inactivation is a critical factor. This poster presents an approach to allow the rapid characterization of human cell lines in ...


Application Of Animal-Free Recombinant Bioactive Protein Supplements To Improve The Performance Of Cell-Based Viral Vaccine Production, Kenneth Bertram, Marina Ross, Domenica Cavallaro, Larissa Chirkova, Geoffrey Francis 2010 Novozymes Biopharma AU

Application Of Animal-Free Recombinant Bioactive Protein Supplements To Improve The Performance Of Cell-Based Viral Vaccine Production, Kenneth Bertram, Marina Ross, Domenica Cavallaro, Larissa Chirkova, Geoffrey Francis

Vaccine Technology III

Animal cell culture for the production of viral vaccines has been performed for more than 50 years, and currently this technology is expanding rapidly to meet present and future demands of the health sector. The development and regulatory approval of continuous cell lines for manufacturing viral vaccines has brought numerous benefits to production processes. However, greater advances in the last decade have been achieved in mammalian cell production of biological therapeutics, including monoclonal antibodies, hormones, growth factors, cytokines and clotting factors. We and others have contributed to these upstream advances by improving cell culture media with the development of animal-free ...


Development Of A Multi-Dose Formulation For Prevnar 13™, Lakshmi Khandke, Cindy Yang, Jingrun Fan, Hanyoung Han, Ksenia Krylova Abbas Rashidbaigi, Bruce A. Green, Kathrin U. Jansen 2010 Pfizer, Pearl River, NY, USA

Development Of A Multi-Dose Formulation For Prevnar 13™, Lakshmi Khandke, Cindy Yang, Jingrun Fan, Hanyoung Han, Ksenia Krylova Abbas Rashidbaigi, Bruce A. Green, Kathrin U. Jansen

Vaccine Technology III

Streptococcus pneumoniae causes up to a million cases per year of invasive disease in young children and infants, most occurring in developing countries. Pfizer is partnering with WHO and the GAVI alliance to support the developing world on immunization against pneumococcal disease. Prevnar 13™ is currently approved for the prevention of invasive pneumococcal disease in twenty seven countries. If used widely, this pneumococcal conjugate vaccine could prevent hundreds of thousands of additional cases of child mortality each year.

Use of single-dose preservative-free vaccine formulations will raise the overall cost of vaccination programs and may jeopardize the effectiveness of immunization programs ...


Co2 Conversion To Organic Compounds And Polymeric Precursors, Jussara Lopes de Miranda 2010 Federal University of Rio de Janeiro, Brazil

Co2 Conversion To Organic Compounds And Polymeric Precursors, Jussara Lopes De Miranda

CO2 Summit: Technology and Opportunity

No abstract provided.


Metabolic Engineering Of A Strain Of Saccharomyces Cerevisiae Capable Of Utilizing Xylose For Growth And Ethanol Production, Ashley Fulton 2010 University of Saskatchewan, Canada

Metabolic Engineering Of A Strain Of Saccharomyces Cerevisiae Capable Of Utilizing Xylose For Growth And Ethanol Production, Ashley Fulton

CO2 Summit: Technology and Opportunity

No abstract provided.


Development Of Inactivated Polio Vaccine From Attenuated Sabin Strains For Clinical Studies And Technology-Transfer Purposes, Yvonne E. Thomassen, Wilfried A.M. Bakker, Janny Westdijk, Aart G. Van ‘t Oever, Nico Van den Heuvel, Jan Hendriks, Gideon F.A. Kersten, Leo A. Van der Pol 2010 Netherlands Vaccine Institute

Development Of Inactivated Polio Vaccine From Attenuated Sabin Strains For Clinical Studies And Technology-Transfer Purposes, Yvonne E. Thomassen, Wilfried A.M. Bakker, Janny Westdijk, Aart G. Van ‘T Oever, Nico Van Den Heuvel, Jan Hendriks, Gideon F.A. Kersten, Leo A. Van Der Pol

Vaccine Technology III

Recently, responding to WHO’s call for new polio vaccines, the development of Sabin-IPV (injectable, formalin-Inactivated Polio Vaccine, based on attenuated ‘Sabin’ polio virus strains) was initated at NVI. This activity plays an important role in the WHO polio eradication strategy. The use of Sabin instead of wild-type Salk polio strains will provide additional safety during vaccine production. Initially, the Sabin-IPV production process will be based on the scale-down model of the current, and well-established, Salk-IPV process. In parallel, process development, optimization and formulation research is being carried out to further modernize the process and reduce cost per dose. The ...


Rabies Virus Glycoprotein (Rvgp) Expression In Drosophila S2 Cells And By Semliki Forest Virus (Sfv). Synthesis And Protection Studies, Carlos Pereira 2010 Instituto Butantan, Brazil

Rabies Virus Glycoprotein (Rvgp) Expression In Drosophila S2 Cells And By Semliki Forest Virus (Sfv). Synthesis And Protection Studies, Carlos Pereira

Vaccine Technology III

Here we report the utilization of Drosophila melanogaster Schneider 2 (S2) cells and the Semliki Forest Virus (SFV) expression system to produce the rabies virus glycoprotein (RVGP). Although they represent different expression systems, they offer similar advantages in generating high-level expression of functional membrane proteins. They are both relatively easy and safe to handle and are scalable. RVGP synthesized by S2 cells and SFV carrying an mRNA coding for RVGP (SFV-RVGP) were assayed in mouse protection studies. We have constructed S2 gene vectors with the hygromycin selection gene (H) in which the RVGP gene is inserted under the control of ...


Digital Commons powered by bepress